TABLE 1.

Included patients.

Patient ID	Sample	Age at onset	Sex	Pathological diagnosis (WHO 2016)	Pathological diagnosis (WHO 2021)	Post operative treatment on initial onset	IDH1/2_status	1p/19q_codel	CDKN2A/B	CDK4	Tumor purity
HM1	HM1_LGG	34	M	DA	Astrocytoma, IDH‐mutant, CNS WHO G2	60Gy_Radiation	IDH1_R132H	None	Intact	Intact	0.66
	HM1_HGG	43	M	sGBM	Astrocytoma, IDH‐mutant, CNS WHO G4				Homozygous deletion	Amplified	0.76
HM2	HM2_LGG	39	M	DA	Astrocytoma, IDH‐mutant, CNS WHO G2	None	IDH1_R132H	None	Intact	Intact	0.76
	HM2_HGG	40	M	sGBM	Astrocytoma, IDH‐mutant, CNS WHO G4				Intact	Amplified	0.68
HM3	HM3_LGG	36	F	DA	Astrocytoma, IDH‐mutant, CNS WHO G2	None	IDH1_R132H	None	Intact	Intact	0.84
	HM3_HGG	38	F	AA	Astrocytoma, IDH‐mutant, CNS WHO G3				Heterozygous deletion	Intact	0.88
HM4	HM4_LGG	56	M	DA	Astrocytoma, IDH‐mutant, CNS WHO G2	None	IDH1_R132H	None	Intact	Intact	0.80
	HM4_HGG	57	M	AA	Astrocytoma, IDH‐mutant, CNS WHO G4				Homozygous deletion	Intact	0.81
HM5	HM5_LGG	30	M	DA	Astrocytoma, IDH‐mutant, CNS WHO G2	None	IDH1_R132H	None	Intact	Intact	0.82
	HM5_HGG	37	M	AA	Astrocytoma, IDH‐mutant, CNS WHO G4				Homozygous deletion	Intact	>0.9

Note: LGG: Before malignant transformation, HGG: After malignant transformation.

Abbreviations: 1p/19q_codel, chromosomal 1p/19q co‐deletion; AA, anaplastic astrocytoma; DA, diffuse astrocytoma; HGG, high‐grade glioma; IDH, isocitrate dehydrogenase; LGG, low‐grade glioma; sGBM, secondary glioblastoma; WHO, World Health Organization.